InvestorsHub Logo
Followers 56
Posts 8436
Boards Moderated 0
Alias Born 05/14/2015

Re: None

Wednesday, 11/16/2022 9:19:34 PM

Wednesday, November 16, 2022 9:19:34 PM

Post# of 118415
The CON that Koos is playing, straight from the 10K

Read this carefully, especially the last part of who got the remaining shares of ONPH that Koos had.

During the quarter ended December 31, 2021 the Company paid $5,000 of rental expenses to the landlord of BST Partners as consideration to BST Partners for use of office space. BST Partners is controlled by David R. Koos the Chairman and Chief Executive Officer of the Company.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

On August 8, 2022 the Company sold 18,200 common shares of Oncology Pharma, Inc. to Zander Therapeutics, Inc. for consideration consisting of $25,000 cash.



Koos makes an EASY $60 in Rent by paying Regen's rent to BST, his other company. How convenient is that? All of his companies are in one way or another paying each other to, in effect, line Koos' pockets.

It is his three card monty shell game tactic of making sure he can afford his boat, boat slip, and service on his expensive Italian Sports car.

Why hasn't the SEC investigated this sleaze ball? Or maybe the the resident Regen message board lawyer can show us how all of this is legal? Maybe I just don't get it.

FACTS are stubborn things